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AbstrAct
Meningiomas are usually considered to be benign central nervous system tumors; 
however, they show heterogenous clinical, histolopathological and cytogenetic 
features associated with a variable outcome. In recent years important advances 
have been achieved in the identification of the genetic/molecular alterations of 
meningiomas and the signaling pathways involved. Thus, monosomy 22, which is 
often associated with mutations of the NF2 gene, has emerged as the most frequent 
alteration of meningiomas; in addition, several other genes (e.g. AKT1, KLF4, TRAF7, 
SMO) and chromosomes have been found to be recurrently altered often in association 
with more complex karyotypes and involvement of multiple signaling pathways. Here 
we review the current knowledge about the most relevant genes involved and the 
signaling pathways targeted by such alterations. In addition, we summarize those 
proposals that have been made so far for classification and prognostic stratification 
of meningiomas based on their genetic/genomic features.
IntroductIon
Meningiomas are one of the most frequent primary 
brain neoplasias –30-35% of all cerebral nervous system 
(CNS) tumors–, which originate from the meningeal 
coverings of the brain and the spinal cord [1]. Despite 
most meningiomas correspond to histologically benign 
(i.e. WHO grade I) slow growing tumors [2], as a whole 
they display a broad spectrum of clinical, histological and 
cytogenetic features, even within the same WHO grade 
[3]. 
In recent years, important advances have been 
achieved in the identification and characterization of 
the genetic and molecular alterations of meningiomas 
and their association with the behavior of the disease. 
Consequently several chromosomal regions and candidate 
targeted genes have been identified. Monosomy 22/
del(22q) in association or not with various mutations of the 
NF2 gene, is by far the most frequent cytogenetic event, 
potentially occurring at the early stages of the disease; 
however, other isolated chromosomal alterations and 
gene mutations, together with more complex karyotypes, 
have also been reported in meningiomas at relatively high 
frequencies, usually in association with a more aggressive 
tumor behavior [4]. 
Here we review the most relevant genetic and 
molecular alterations described so far in meningiomas, 
particularly focusing on the most frequently altered 
chromosomes, genes and signaling pathways.
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Genetic alterations of chromosome 22 in 
meningiomas
Monosomy 22 in association or not with mutation 
of the NF2 gene, is by far the most frequent chromosomal 
alteration in meningiomas although other genes in this 
chromosome, as well as other chromosomes have also 
been found to be recurrent altered in these tumors (Table 
1).
the nF2 gene and the merlin protein
A high proportion of meningiomas display recurrent 
genetic alterations of chromosome 22 and the NF2 tumor 
suppressor gene coded in the long arm of chromosome 
22 (22q). Accordingly, monosomy 22 is found in around 
half of meningioma cases, the great majority of NF2-
associated meningiomas, as well as between 40-70% of 
sporadic meningiomas, displaying allelic losses (loss of 
heterozygosity, LOH) at the 22q12.2 chromosomal region, 
where the NF2 gene is encoded [1, 3]. Additionally, up to 
60% of these meningiomas carry inactivating mutations 
in the remainder NF2 allele [1, 5], consistent with the 
classical two-hit hypothesis of tumor suppressor gene 
inactivation. So far, a range of NF2 mutations have been 
reported in meningiomas most of which consist of small 
insertions, deletions, or nonsense mutations affecting the 
splicing sites [1, 6]. As the frequency of NF2 mutation 
is roughly equal among the different WHO grades, it 
has been considered a relevant genetic alteration in 
tumor initiation rather than in malignant progression [1, 
table 2: Genetic markers of meningiomas which have been associated with  an  independent prognostic value on 
patient relapse-free survival (rFs).
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3]. Despite Lomas et al. [7] have reported that the NF2 
gene may be alternatively inactivated in meningiomas by 
aberrant promoter methylation, later studies indicated that 
methylation of the NF2 promoter does not play a major 
role in meningioma development [8, 9].
The merlin protein (also known as schwannomin) 
is the product of the NF2 gene. Merlin is a member of 
the 4.1 family of proteins which link integral membrane 
proteins to the cytoskeleton, and that are involved in 
the regulation of cell growth, proliferation and motility. 
Meningioma-associated NF2 mutations commonly result 
in a truncated, non-functional protein, which may lead to 
abnormal cell growth and motility through destabilization 
of adherens junctions. The main characteristic of cells 
lacking the NF2 protein is the loss of contact-mediated 
inhibition of cell proliferation [5]. Additionally, loss of 
merlin activity has been associated with increased levels 
of ErbB receptors in primary Schwann cells, which 
regulate downstream mitogenic signaling pathways (e.g. 
Ras/Raf/MEK/ERK and PI3K/AKT); altogether, these 
findings support a relevant role of merlin in tumorigenesis 
in meningiomas [10]. In line with this hypothesis, 
mice which are heterozygous for NF2 mutations more 
frequently develop metastatic tumors, and both in vivo and 
in vitro re-expression of wild type merlin leads to reduced 
tumor growth and decreased cell motility [3, 11]. 
Figure 1: schematic diagram illustrating the key elements of some of the most relevant signaling pathways involved 
in the pathogenesis of meningiomas. The Ras-Raf-MEK-MAPK/ERK, PI3K-Akt/PKB, PLCγ1-PKC, PLA2-COX, JAK-STAT3 and 
mTOR signaling pathways are represented in the upper part of the scheme, while the relationships between the pRb and p53 cell cycle 
associated signaling pathways are illustrated in the lower part of the scheme. The pathway scheme displayed was generated with the 
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems Inc., Redwood City, CA, USA)
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Since the merlin functions include linking membrane 
proteins to the cytoskeleton, it has been hypothesized that 
alterations in merlin may substantially affect cell shape 
and might favor the appearance of a more mesenchymal-
like phenotype rather than the epithelioid one, which is 
more commonly observed in wild type NF2 meningiomas 
[1]. Of note, several studies have reported different 
frequencies of NF2 mutation in meningiomas displaying 
distinct histopathological features; thus, alterations (e.g. 
monosomy) of chromosome 22q are more frequently 
observed in transitional and fibrous meningiomas than 
in the meningothelial variant [12, 13]. In addition, an 
association between the NF2 gene and tumor localization 
has also been reported; Kros et al. [13] demonstrated 
that tumors of the convexity are more prone to have NF2 
mutations than anterior cranial-based tumors, and Clark 
et al. [14] recently correlated meningiomas with mutant 
NF2 and/or chromosome 22 loss with tumor localization 
in the cerebral and cerebellar hemispheres. In line with 
the unique features associated with NF2 mutation in 
meningiomas, an association with postmenopausal women 
tumors carrying monosomy 22 has also been reported 
recently [6].
other candidate genes coded in chromosome 22
Although NF2 is the most frequently altered gene 
in chromosome 22, the frequency of deletions at this 
chromosomal region exceeds by far that of NF2 mutations 
in meningioma, suggesting that other genes encoded at 
chromosome 22 may also be involved in meningioma 
tumorigenesis. In this regard, an early report found BAM22 
–a gene from the β-adaptin family coded at chromosome 
22q12– to be inactivated in 9/71 meningiomas [15], and 
another more recent study found reduced expression 
of the BCR (breakpoint cluster region) gene coded at 
chromosome 22q11 in meningiomas with 22q LOH [16], 
further supporting the existence of candidate genes other 
than NF2 in the pathogenesis of meningiomas (Table 1). 
Tissue inhibitors of metalloproteinases (TIMP) 
are proteins that regulate matrix metalloproteinases 
(MMP) and thereby also cell proliferation, apoptosis, and 
angiogenesis. The TIMP3 gene is coded at chromosome 
22q12, is currently the best understood tumor suppressor 
gene being altered by epigenetic mechanisms in 
meningiomas [9]; of note epigenetic inactivation of TIMP3 
has been recently associated with a more aggressive and 
higher-grade (grade II-III) meningioma phenotype [9, 17, 
18]. 
other relevant chromosomes and genes in 
meningiomas
In addition to monosomy 22/del(22q), other 
isolated and combined chromosomal alterations have 
also been identified in meningiomas. Thus, losses of 
chromosomes 1p, 10, 14/14q, and less frequently also 
of chromosomes 6q, 9p, 18q and the sex chromosomes, 
together with gains of chromosomes 1q, 9q, 12q, 15q, 17q, 
and 20q, have all been recurrently detected in a variable 
proportion of cases that overall account for around 30% 
of all meningiomas [1, 4, 19-22]. Of note, several genes 
coded in these chromosome have been recently identified 
by next generation sequencing as recurrently altered in 
meningiomas; among others, these include the AKT1 
(E17K mutation), SMO (L412F and W535L mutations), 
KLF4 (K409Q mutation) and TRAF7 (several mutations 
mapped at the WD40 domains) genes [14, 23, 24]. Most 
interestingly, such mutations were shown to correlate 
with specific clinico-histopathological characteristics 
(e.g. tumor localization and histopathological subgroups) 
as well as with a subset of meningiomas lacking NF2 
mutation, bringing new insight into NF2 non-mutated 
tumors [14, 23, 24].
Despite several other candidate genes have been 
proposed to be targeted by these chromosomal alterations, 
the specific relevant genes involved in many of them, still 
remain most frequently unknown. 
Genetic alterations of chromosome 1
Chromosome 1p deletions comprise the second 
most common chromosomal alteration in meningiomas [1, 
3]. Del(1p) is typically associated with more aggressive 
meningiomas, its frequency increasing from grade I (13-
26%) to grade II (40-76%) and grade III (70-100%) tumors 
[3, 25]; from the clinical point of view, loss of chromosome 
1p is also associated with higher tumor recurrence rates 
[26, 27] (Table 1). The most frequently targeted regions of 
chromosome 1p involve the 1p33-34 and 1p36 cytobands 
[4], where several candidate genes have been identified, 
e.g. TP73, CDKN2C, EPB41, GADD45A, and ALPL 
[3]. However, current results do not support a key role 
in tumorigenesis and/or malignant progression for most 
of these genes as meningioma-specific tumor suppressors 
namely CDKN2C, EPB41 and GADD45A, since they all 
failed to show consistent structural alterations. In contrast, 
although mutation of the TP73 gene has not been found, 
methylation-mediated inactivation of TP73 has been 
recurrently reported as frequent in meningiomas [17, 
28]. Similarly, evidences exist about the potential role of 
the ALPL gene that encodes for the alkaline phosphatase 
enzyme at 1p36.1-34, as a tumor suppressor gene, because 
loss of chromosome 1p in meningiomas is strongly 
associated with loss of alkaline phosphatase activity [20], 
a predictor of meningioma recurrence [29]. Despite this, 
mutational analysis of ALPL has not been reported so far 
in the literature.
In turn, gains of chromosome 1q mainly involving 
two chromosomal regions (1q25.1 and 1q25.3 to 
1q32.1), have been reported in around 60% of atypical 
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meningiomas [30]. From the prognostic point of view, 
gains of chromosome 1q have been recurrently associated 
with a shorter progression-free survival [30]. However, 
detailed examination and identification of those genes 
with oncogenic potential which may be coded in this 
chromosome arm, still deserves further investigation. 
Genetic alterations of chromosome 6
Genetic losses involving the long arm of 
chromosome 6 are a relatively common finding in 
meningiomas, particularly among high grade tumors; 
reported frequencies range from 9% of grade I to 25-33% 
of grade II and 50-63% of grade III meningiomas [4, 21, 
25] (Table 1). A common deleted segment at chromosome 
6q includes the 6q24.1-qter region, where the ESR1, 
IGF2R [4], DLL1, and CTGF [31] cancer-associated genes 
are encoded. However, the functional role of these genes 
and the impact of their alterations in meningiomas are still 
far from being fully understood. In addition to del(6q), 
Pérez-Magán et al. [31] also reported overexpression 
of the histone cluster 1 genes coded at chromosome 6p 
(e.g. the HIST1H1c gene) in 27% and 89% of primary 
and recurrent meningiomas, respectively; recent results 
suggest that physical interaction of the H1.2 protein could 
be involved in epigenetic regulation of gene expression 
by maintaining specific DNA methylation patterns, but 
its functional role in meningiomas still remains to be 
elucidated. 
Genetic alterations of chromosome 9
Genetic losses at chromosome 9p have been reported 
in 5-17% of grade I, 18-52% of grade II, and 38-74% of 
grade III meningiomas [3] (Table 1). In contrast with 
other chromosomal alterations, the role of chromosome 
9 in the development of malignant meningiomas is 
better defined, since it has been mostly associated with 
three tumor suppressor genes coded at chromosome 
9p21: CDKN2A/p16INKa, CDKN2A/p14ARF and CDKN2B/
p15ARF. Proteins coded by these three genes are all well 
known to play an important role in cell cycle regulation 
and apoptosis; thus p16INKa and p15ARF regulate cell cycle 
progression at the G1/S-phase checkpoint by inhibiting 
cyclin-cdk complexes, whereas p14ARF regulates apoptosis 
through a blockade of MDM2-mediated degradation of 
p53 [3]. In addition, homozygous deletion and somatic 
mutation of these genes have been reported in anaplastic 
meningiomas, supporting the notion that inactivation of 
cell cycle regulation is an important feature of malignant 
progression [32]. For example, Boström et al. [33] found 
homozygous deletions of CDKN2A/p16INKa, CDKN2B/
p15ARF and CDKN2A/p14ARF in 46% of anaplastic vs. 3% 
of atypical meningiomas. In a similar way, Goutagny 
et al. [34] have recently shown by SNP-arrays that the 
most frequent genomic alteration of meningiomas upon 
progression to grade III was loss of CDKN2A/CDKN2B. 
Additionally, inactivation through hypermethylation of 
CpG islands has also been reported in a smaller proportion 
of meningiomas, including hypermethylation of CDKN2A/ 
p16INKa in 8-17% of cases, CDKN2A/p14ARF in 4-13%, and 
CDKN2B/p15ARF in 4% of these tumors [17, 35]. All such 
correlations also appear to have a prognostic impact since 
meningiomas with 9p21 losses have a significantly shorter 
survival and a worse clinical outcome than cases showing 
no alterations of chromosome 9p21 [36]. In addition to the 
CDKN2A/CDKN2B genes, the KLF4 (Kruppel like factor 
4) gene has also been recently reported to be mutated in 
meningiomas (particularly among secretory tumors) in 
association with lack of NF2 mutation.
Genetic alterations of chromosome 10
Losses of part or the whole chromosome 10 are 
present in a significant proportion of meningiomas, their 
frequency increasing from grade I (5-12%) to grade II 
(29-40%), and grade III (40-58%) tumors [3, 25, 37]. In 
addition, LOH at specific regions of chromosome 10 have 
been associated with both higher recurrence rates and a 
poorer survival [37]. Some of the potential candidate genes 
encoded in such chromosomal regions (e.g. 10q23-q25) 
include the PTEN, MXI1 and DMBT1 genes, but studies 
have failed to identify frequent/recurrent mutations of 
these genes in meningiomas [38].
More recently, Dobbins et al. [39] identified a new 
susceptibility locus for meningioma at chromosome 
10p12.31, which encompasses the MLLT10 (myeloid/
lymphoid or mixed-lineage leukemia translocated to 
10) gene; this gene is involved in chromatin remodeling 
and modulation of transcription. However, further 
investigations about the potential role of this gene in 
meningiomas are still needed. 
Genetic alterations of chromosome 14
Overall, monosomy 14/del(14q) represents the third 
most common chromosomal alteration in meningiomas, 
being present in up to 31% of grade I, 40–70% grade II, 
and up to 100% of grade III meningiomas [40]. From 
the prognostic point of view, the chromosome 14q 
status has been identified as a prognostic indicator for 
tumor recurrence [40, 41]. Because of this, among other 
chromosome 14 regions, the 14q32 region has been 
suggested to be potentially relevant for meningioma 
progression. In this regard, Zang et al. [42] have identified 
the maternally expressed gene 3 (MEG3) coded in this 
chromosomal region, as a candidate tumor suppressor 
gene with antiproliferative activity. MEG3 is an imprinting 
gene that encodes for a non-coding RNA. In meningiomas, 
loss of MEG3 expression, its deletion at the genomic DNA 
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and the degree of methylation of its promoter, have all 
been associated with higher tumor growth [43] (Table 
1). In turn, functional studies have demonstrated that 
MEG3 mediates its anti-tumoral effect through inhibition 
of DNA synthesis, colony formation and proliferation of 
meningioma cell lines, being also found to transactivate 
p53 [42]. Altogether, these findings suggest that MEG3 
may have an important role as a novel long non-coding 
RNA tumor suppressor in meningiomas. Recently, the 
AKT1 gene (coded at chromosome 14q32) has been 
reported to be mutated in meningiomas lacking NF2 
mutation [14, 23], the reported mutation (E17K) resulting 
in constitutive AKT1 activation [23]; therefore, the AKT1 
gene has become one of the most attractive target genes 
for cases with monosomy 14/del(14q).
Of note, the N-myc downstream-regulated gene 
2 (NDRG2) has also been identified as a potential 
tumor suppressor gene coded at chromosome 14q11.2. 
Accordingly, NDRG2 was found to be frequently 
downregulated at both the transcript and the protein levels 
in anaplastic meningiomas and in a subset of lower-grade 
and atypical cases with an aggressive clinical behavior 
[44], as well as in recurrent meningiomas [45]. Reduced 
expression of NDRG2 appears to be closely associated 
with hypermethylation of its promoter [44]. Despite the 
precise mechanism of action of NDRG2 remains largely 
unknown, this gene has been involved in the regulation of 
cell growth, differentiation and apoptosis [9]. 
Genetic alterations of chromosome 17
Chromosome 17 gains and/or amplification of the 
17q21-qter chromosomal region have been recurrently 
reported, mostly in malignant meningiomas [4]. RPS6K 
(ribosomal protein S6 kinase; p70S6K) is a proto-oncogene 
coded at chromosome 17q23, which has been found 
to be overexpressed at the protein level [46]; however, 
amplification of this gene appears to occur only in a 
small subset of higher grade meningiomas, even when 
amplification of the loci adjacent to this gene is present 
[47], suggesting that other genes coded in the vicinity of 
RPS6K may be the main targets for 17q amplification. 
In this regard, recent studies have also investigated the 
potential role of STAT3 (coded at 17q21.2), showing a 
higher frequency of enhanced expression of STAT3 with 
increasing tumor grade [48] (Table 1). Zhang et al. [48] 
further reported that constitutively active STAT3 was 
significantly associated with expression of the vascular 
endothelial growth factor (VEGF), a major inducer of 
tumor angiogenesis, and Johnson et al. [49] suggested 
that the cerebrospinal fluid itself may act as a stimulus for 
STAT3 phosphorylation/activation. 
Genetic alterations of chromosome 18
Losses at chromosome 18q have been recurrently 
reported in meningiomas [3, 4, 50]; however, the specific 
targeted genes still remain to be identified. The expression 
of the bcl-2 oncoprotein coded at 18q21.3, has been 
associated with both a higher tumor grade and recurrence 
rate [51, 52]. In parallel, due to the role of the merlin 
protein in meningioma tumorigenesis, several studies 
have further investigated other members of the 4.1 family 
of membrane-associated proteins coded at chromosome 
18q. These include the DAL-1 (differentially expressed in 
adenocarcinoma of the lung) gene which encodes for the 
4.1B protein and has been claimed to act as a potential 
tumor suppressor gene in meningiomas [53]. Thus, loss 
of heterozygosity of DAL-1 at chromosome 18p11.32 
was initially reported to occur in 60-76% of sporadic 
meningiomas [54], independently of the histological 
grade, suggesting that it could represent an early event in 
the pathogenesis of the disease (Table 1). However, more 
recent studies showed conflicting results. Thus, Yi et al. 
[55] reported that transgenic mice lacking DAL-1 do not 
develop tumors, and Nunes et al. [56] reported that only 
12/62 (19%) meningiomas had LOH of DAL-1, 11 of such 
12 cases also showing LOH of the NF2 gene. Altogether, 
these results suggest that DAL-1 may be involved in 
progression rather than initiation of meningiomas, as 
supported by the presence of monosomy 18 and/or 
del(18p) in 3/4 WHO grade II tumors vs. 2/13 WHO grade 
I meningiomas [56]. Other recent reports in meningiomas 
found no losses involving the genomic regions which 
contain the DAL-1 gene [8, 23], and another study found 
this gene to be mutated at a very low frequency [57].
Altered signaling pathways in meningiomas
At present, it is well known that most of the above 
described genetic alterations have an impact on one or 
more signaling pathways which are recurrently involved in 
cancer. The most relevant and frequently altered signaling 
pathways in meningioma are reviewed in this next section 
and illustrated in Figure 1.
the rb/p53 pathways and its impact on cell cycle 
dysregulation
RB has a central role in the inhibition of cell 
cycle progression at the G1/S-phase checkpoint. Briefly, 
RB binds (and inhibits) to the E2F transcription factor. 
Once cyclin D expression is upregulated (e.g. under 
mitogenic stimuli) it binds to either Cdk4 or Cdk6, and 
phosphorylates RB; RB phosphorylation induces release 
of the active E2F factor, leading to the transcription of 
genes which are critical for the transition from the G1 to 
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the S-phase. p16INK4a and p15INK4b prevent S-phase entry 
by inhibiting the Cdk4/cyclin D complex [3]. In turn, 
the p53 pathway acts as a feedback inhibitor of the RB 
pathway, by inducing cell cycle arrest, DNA repair and 
apoptosis in case of aberrant RB pathway activation 
(Figure 1). The RB and p53 pathways are connected via 
p14ARF. Release of the E2F transcription factor following 
RB phosphorylation, also induces transcription of p14ARF, 
which promotes p53 activity through negative regulation 
of the MDM2 (murine double minute 2 protein) proto-
oncogene. Dysregulation of these two pathways in higher-
grade meningiomas is frequently associated with loss of 
p16INK4a, p15INK4b and p14ARF, increased cell proliferation 
and tumor progression [33, 34]. In addition, accumulating 
evidences indicate that hypermethylation- associated loss 
of function of RB [8, 58], overexpression of the MDM2 
gene/protein [25, 26] and loss of expression of MEG3 (an 
anti-proliferative tumor suppressor that induces activation 
of p53 by a transcriptional effect) [42] in higher grade 
meningiomas, might further contribute to dysregulation of 
both cell cycle-associated pathways during meningioma 
progression. 
Growth factors and autocrine loops
Multiple studies have demonstrated enhanced 
expression of several growth factors, and activation of 
autocrine loops, which act as extra- and intracellular 
signals that induce tumor growth, cell migration, and 
angiogenesis, mostly via the MAPK and PI3K/Akt 
signaling pathways (Figure 1). Among others, the platelet-
derived growth factor BB (PDGF-BB) and its PDGFR-β 
receptor have been found to be frequently overexpressed 
in meningiomas (typically at greater levels in high vs. low 
grade tumors), leading to meningioma cell proliferation 
via an autocrine and/or paracrine loop. Similarly, the 
epidermal growth factor receptor (EGFR), and both 
their EGF and transforming growth factor-alpha (TGFα) 
ligands, as well as some members of the insulin-like 
growth factor (IGF) system (e.g. IGF2) [59], have all been 
associated with meningioma cell proliferation and tumor 
progression. Interestingly, Lallemand et al. [10] reported 
that merlin regulates cell contact-mediated inhibition of 
proliferation by limiting the delivery of several growth 
factor receptors (e.g. ErbB2, ErbB3, IGF1R and PDGFR) 
at the plasma membrane of primary Schwann cells, and 
thereby inhibit the activity of the downstream mitogenic 
signaling pathways. 
VEGFA and its VEGFR-1 receptor have been 
associated with regulation of the development of new 
blood vessels and peritumoral edema in brain tumors, 
a common feature in meningioma patients [3]. Of note, 
meningiomas express both VEGF and VEGFR, and VEGF 
expression correlates with the severity of peritumoral 
edema [60, 61] and tumor vascularization [61]. Despite 
this, the precise mechanisms that regulate VEGF 
expression in meningiomas remain unknown. In human 
cells, VEGF is mainly regulated by the hypoxia inducible 
factor-1 (HIF-1) transcription factor and in meningiomas, 
HIF-1 expression correlates with VEGF expression and 
the degree of peritumoral edema. In addition, upregulation 
of VEGF expression can also be induced by other growth 
factors such as EGF and PDGF, suggesting that both 
growth factors and hypoxia stimulation may all contribute 
to control VEGF expression in these tumors. 
Other growth factors that have been associated 
with the pathogenesis of meningiomas include: 1) the 
stromal cell-derived factor 1 (SDF1) CXC chemokine 
and its CXCR4 receptor, which might exert its mitogenic 
effects through the MAPK pathway [62]; 2) the bone 
morphogenic proteins (BMPs) and their receptors 
(BMPR), which are associated with Smad 1 signaling, 
and; 3) the fibroblast growth factor (FGF) and its FGFR3 
receptor, which are activated by the PI3K/Akt pathway 
[63]. In contrast, TGF-β and its receptors (TGF-βRI and 
TGF-βRII) may act as potential inhibitors of meningioma 
growth/proliferation through the Smad 2/3 apoptotic 
pathway [64], although the role of TGF-β in meningioma 
tumorigenesis remains to be fully established. 
the MAPK and PI3K/Akt signaling pathways
The mitogen-activated protein kinase (MAPK) 
pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway are both involved in multiple cellular processes 
(e.g. differentiation, growth, and apoptosis) associated with 
the pathogenesis of meningiomas, particularly with those 
tumors showing deregulated cell proliferation [3]. MAPKs 
are intracellular serine/threonine-specific protein kinases 
which are activated by extracellular stimuli (e.g., mitogen 
signals), leading to sequential activation of a kinase 
cascade triggered by the Ras/Raf-1/MEK-1/MAPK/ERK 
pathway and that ultimately, leads to phosphorylation/
activation of transcription factors in the nucleus [64]. 
PI3Ks are a family of intracellular signal transducer 
enzymes that phosphorylate inositol phospholipids. 
Activation of PI3K results in phosphorylation/activation of 
PKB/Akt and subsequently p70S6K, which are key elements 
of the cell growth-promoting effects of this pathway; 
alternatively, activating mutations of AKT have also been 
recently reported in a subset of meningiomas [64]. In 
line with this, Johnson et al. [63] found evidences for the 
activation of both the MAPK and the Akt/PKB pathways 
in meningiomas, upon growth factor receptor signaling via 
e.g. PDGF-BB and PDGFβ; furthermore, these authors 
showed that administration of MAPK or PI3K inhibitors 
induces progressive growth inhibition of meningioma cells 
in association with reduced phosphorylation of MAPK or 
Akt and p70S6K, respectively. Interestingly, Mawrin et al. 
[65] have also found higher levels of phospho-Akt/PKB 
in association with lower levels of activation of MAPK 
in anaplastic and atypical vs. benign meningiomas; 
moreover, in vitro studies revealed decreased meningioma 
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cell growth in the absence of apoptosis induced by a PI3K 
blocker, whereas inhibition of MAPK resulted in cell 
death through apoptosis [65]; based on these findings, 
the authors hypothesized that PI3K/Akt activation 
is associated with uncontrolled growth in malignant 
meningiomas, whereas MAPK activation appears to 
be involved in both meningioma cell proliferation and 
apoptosis [65].
The PLCγ/PKC-calcium signaling pathway
Tyrosine kinase receptors also activate (e.g. 
phosphorylate) phospholipase C-γ1 (PLC-γ1), leading to 
hydrolysis of PIP2 (phosphatidylinositol 4,5-biphosphate) 
into two intracellular active second messengers: 
IP3 (inositol 1,4,5-triphosphate) and 1,2-DAG 
(1,2-diacylglycerol) (Figure 1). DAG activates protein 
kinase C (PKC), which enters the nucleus and activates 
transcription factors, resulting in cell proliferation and 
inhibition of apoptosis [64]. The activation of the EGFR 
kinase in meningioma cells further activates PLC-γ1 
and increases its catalytic activity, leading to another 
mechanism that promotes meningioma cell growth; 
additional evidences indicate that PLCγ expression 
does not differ significantly between meningiomas of 
different histopathological grades [65]. In turn, IP3 
mediates calcium release from intracellular stores 
resulting in increased free cytosolic calcium. Interestingly, 
calcium channel antagonists can block in vitro primary 
meningioma cell growth after stimulation with EGF 
and PDGF, as well as in vivo meningioma growth in a 
subcutaneous meningioma mouse model [66]; the specific 
mechanisms involved in such blockade of IP3-mediated 
intracellular calcium signaling pathways in meningiomas, 
still deserves further investigation. 
the cyclooxygenase-2 signaling pathway
The phospholipase A2 (PLA2)-cyclooxygenase 
(COX) signaling pathway has also been recently 
investigated in meningiomas [64]. COX-2 is an enzyme 
that serves as the rate-limiting step for the synthesis of 
prostaglandins from arachidonic acid. Prostaglandins 
(e.g. PGE2) are mediators of several critical cellular 
processes such as cell growth, proliferation, angiogenesis, 
suppression of apoptosis, and inflammation [3]. Normally, 
the cytoplasmic levels of arachidonic acid are relatively 
low, which limits the production of prostaglandins. 
However, altered levels of arachidonic acid and COX-2 
overexpression have been associated with cancer growth 
and progression, possibly driven by signaling pathways 
such as those involving growth factors and the MAPK 
pathway [64]. Of note, high levels of arachidonic acid, 
increased prostaglandin production, as well as COX-
2 overexpression [26, 67, 68], have all been reported in 
meningiomas. Moreover, COX-2 expression has been 
correlated with a greater degree of invasiveness to the 
brain or the adjacent soft tissues [67], tumor recurrence 
[26], a higher MIB-1 labeling index [68] and VEGF levels 
[67, 68], suggesting it may play an important role in the 
development and growth of meningiomas.
the mtor signaling pathway
Recent studies have found the mammalian target of 
rapamycin (mTOR) to be also involved in the signaling 
pathways associated with meningioma tumorigenesis 
[69, 70]. mTOR is a protein kinase that may be expressed 
in two distinct complexes (mTORC1 and mTORC2). 
mTORC1 regulates cell growth by promoting increased 
translation and protein synthesis through phosphorylation 
of the p70S6K and 4EBP1 (eukaryotic translation initiation 
factor 4E-binding protein 1) effector proteins; in turn, 
mTORC2 directly phosphorylates Akt, a step required 
for its full activation [1, 3]. Recently, merlin has been 
identified as a negative regulator of mTORC1 and, James 
et al. [69] have demonstrated that mTORC1 levels are 
elevated in tumors derived from patients with NF2 disease 
and in fibroblasts from an NF2-deficient mouse model. 
Thus, activation of mTORC1 has been associated with 
meningioma growth [69], and mTORC1 inhibitors have 
been shown to suppress meningioma growth in mouse 
models [70]. However, the exact mechanism through 
which merlin inhibits mTORC1 still remains unclear. 
In contrast to its effects on mTORC1, merlin positively 
regulates the kinase activity of mTORC2, downstream 
phosphorylation of mTORC2 substrates, including Akt, 
being reduced upon acute merlin deficiency in cells. 
Nevertheless, the attenuated mTORC2 signaling profiles 
reported in response to the loss of merlin, could not be 
detected in NF2-deficient meningiomas [69].
 The WNT/β-catenin pathway
The wingless (wnt)/β-catenin pathway has also 
been implicated in meningioma progression, through an 
altered expression of several of its genes. Thus, early 
studies based on microarray gene expression profiling 
identified increased expression of genes such as CTNNB1, 
CDK5R1, ENC1 and CCND1 [59]. Subsequently, Pecina-
Slaus et al. reported LOH of the E-cadherin (CDH1) 
[71] and the adenomatous polyposis coli (APC) tumor 
suppressor genes in about one-third and half of the cases, 
respectively. Downregulation of E-cadherin expression 
in clinically aggressive and invasive meningiomas 
had already been described [72] in association with 
upregulation and nuclear/perinuclear localization of 
β-catenin [71], suggesting an important role for the 
WNT/β catenin pathway in meningioma tumorigenesis. 
Interestingly, Zhou et al. [73] suggested a model in which 
active merlin would inhibit Wnt/β-catenin signaling and 
maintain β-catenin and N-cadherin complexed at the 
plasma membrane; loss of merlin would then lead to 
loss of contact inhibition and activation of Wnt/β-catenin 
signaling, translocation of β-catenin to the nucleus and 
expression of intracellular growth-associated proteins such 
as c-myc and cyclin D1. 
Interestingly, Pérez-Magán et al. [74] recently 
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reported a gene expression profiling (GEP) signature of 
advanced and recurrent meningiomas, which included 
aberrant expression of genes of the Wnt pathway; thus, 
these authors found downregulation of SFRP1, a gene 
from the SFRPs (secreted frizzled-related proteins) protein 
family which are able to downregulate Wnt signaling, 
in recurrent and atypical meningiomas. Similarly, the 
BCR gene, which typically shows lower expression in 
meningiomas with LOH at chromosome 22q [16], has 
also been shown to act as a negative regulator of the Wnt 
pathway [75]. 
the notch signaling pathway
The notch signaling pathway is involved in 
extracellular-to-intracellular signaling via the notch1-4 
transmembrane proteins. Ligand proteins bind to the 
extracellular portion of the Notch proteins, resulting 
in proteolytic cleavage and release of the intracellular 
portion, which is translocated to the nucleus and initiates 
expression of the hairy/enhancer of split (HES) family 
of transcriptional regulators [3]. Cuevas et al. [76] 
comparatively analyzed the GEP of normal/reactive 
meninges and meningiomas of all histopathological 
grades, and demonstrated the potential involvement of 
the notch signaling pathway in meningiomas. Thus, HES1 
expression was increased in all meningioma grades and 
it correlated with increased expression of notch1, notch2, 
and the jagged ligand [76]; in contrast, transducin-like 
enhancer of split (TLE) 2 and TLE3, two co-repressors 
that modulate HES1 activity, were specifically upregulated 
in malignant meningiomas [76]. Furthermore, deregulation 
of notch in meningiomas results in tetraploidy and 
chromosomal instability [77], further studies being 
required to elucidate the precise mechanism by which 
abnormal notch activation induces such genetic changes 
in meningiomas.
the hedgehog (Hh) signaling pathway
When Hh binds its patched (PTCH) receptor, 
the smoothened (SMO) transmembrane protein is 
activated and initiates a signaling cascade that results 
in the activation of the GLI transcription factors (e.g. 
GLI1 and GLI2) and subsequent transcription of genes 
involved in cell growth, proliferation, angiogenesis, 
matrix remodeling, and stem cell homeostasis [3]. 
Recently, Laurendeau et al. [78] have analyzed the mRNA 
expression patterns of 32 Hh pathway-related genes in 
36 meningiomas and found increased levels of 16 genes 
involved in the activation of the Hh pathway (e.g. SMO, 
GLI1, GLI2, GLIS2, FOXM1, IGF2 and SPP1) and cell 
growth, together with decreased expression of 7 genes 
involved in the inhibition of the Hh pathway (e.g. the 
PTCH1 tumor suppressor); some of these genes further 
showed different expression profiles among tumors of 
different histopathological grades, suggesting distinctly 
altered profiles early during tumorigenesis vs. progression 
to more aggressive tumor lesions. Interestingly, recent 
reports have identified SMO mutations in meningiomas 
lacking NF2 mutations [14, 23], which further supports 
the potentially relevant role of this pathway in the 
development of at least some meningiomas.
cytogenetic subgroups of meningiomas and their 
association with tumor progression
Based on all what has been described above, 
at present it is well-established that meningiomas are 
cytogenetically heterogenous tumors. Consequently, 
for decades now, attempts have been made to classify 
meningiomas on cytogenetic grounds (Figure 2). The 
first cytogenetic classifications and cytogenetic models of 
progression of meningiomas were proposed in the 1990s 
[25]. Weber et al. [25] proposed a model of genomic 
alterations associated with meningioma progression based 
on comparative genomic hybridization (CGH) analysis of 
tumors of different grades (Figure 2). Later on, Ketter et 
al. [19] and Zang et al. [20], subdivided meningiomas 
into four subgroups based on their cytogenetic findings: 
Group 0, included meningiomas with a normal diploid 
chromosomal set; Group 1, consisted of tumors with 
monosomy 22 as the sole cytogenetic alteration; Group 2, 
was composed of tumors showing marked hypodiploidy 
with loss of additional autosomes, and finally; Group 3 
included meningiomas with deletions of the short arm of 
chromosome 1, in association with other chromosomal 
aberrations such as loss of chromosome 22. Later on, 
these same authors applied oncogenetic tree mixtures to 
identify recurrent oncogenetic routes based on specific 
sequences of accumulation of somatic chromosomal 
changes in tumor cells (Figure 2); based on the routes 
identified, a genetic progression score (GPS) was 
built and used to categorize meningiomas into three 
groups of increasingly higher genetic complexity [79]. 
Subsequently, intratumoral cytogenetic patterns of clonal 
evolution have also been evaluated to establish recurrent 
pathways of cytogenetic progression at the single level, 
within individual tumors (Figure 2). Based on these later 
studies, complete or partial loss of either chromosome 
22, a sex chromosome (i.e. chromosome Y in males and 
chromosome X in females), del(1p) or less frequently, 
monosomy 14/14q- alone or in combination with other 
chromosomal losses (e.g., monosomy 10/10q- and 18/18q-
), would frequently represent the earliest detectable 
chromosomal alteration in meningioma cells. Interestingly, 
despite the clear association observed between a more 
advanced tumor grade and a higher number of tumor 
cell clones and complex karyotypes, authors found that 
the pathways of intratumoral clonal evolution observed 
in benign meningiomas were markedly different from 
those most frequently found in atypical/anaplastic tumors; 
altogether, these results suggest that the latter tumors 
might not always represent a more advanced stage of 
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histologically benign meningiomas, but they could more 
likely correspond to stages of distinct clonal evolution 
pathways (Figure 2). For example, while monosomy 
22 is commonly present in the earliest tumor cell clone 
observed in grade I meningiomas, it was only detected in 
a minor proportion of all atypical/anaplastic tumors; in 
contrast, presence of isolated losses of a sex chromosome, 
del(1p) and monosomy 14 in the ancestral tumor cell 
clone were characteristic of atypical/anaplastic tumors 
(Figure 2). In fact, although cytogenetic progression 
from low- to high-grade meningiomas may occur [22], 
it remains controversial [1] and the precise pathways of 
clonal evolution remain to be identified. This is due, at 
least in part, to the fact that data used to explain stepwise 
progression (e.g. cumulative acquisition of genetic 
alterations leading to more aggressive subclones), typically 
Figure 2: Patterns of cytogenetic alterations proposed to reflect cytogenetic progression of meningiomas, according to 
Ketter et al. [79] (panel a), Weber et al. [25] (panel b), and Sayagues et al. [86] (panel c). Panel a, oncogenetic tree mixture model for the 
acquisition of chromosomal alterations in the development of meningiomas; the first two critical steps in the progression model correspond 
to monosomy 22, followed by loss of the short arm of chromosome 1. In the Weber et al model (panel b), progression from grade I to grade 
III is proposed to occur in parallel to the acquisition of specific chromosomal gains and losses at frequencies of more than 30% of cases; 
nevertheless, chromosomal changes may already have occurred in a lower grade in a smaller percentage of tumors. Finally, hypothetical 
intratumoral aneuploidization pathways defined on the basis of the patterns of clonal evolution observed for 11 chromosomes analyzed at 
the single cell level for individual tumors by Sayagues et al. (panel c).
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derives from cytogenetic analyses of different tumors of 
distinct grades, and from different patients. In contrast, 
studies addressing this question through the follow-up of 
patients showing tumor recurrence mostly reported no (or 
only minor) cytogenetic changes at recurrence, even after 
progression to a higher histopathological tumor grade [80]. 
From a clinical point of view, both the cytogenetic 
and genomic profile of meningiomas has recurrently been 
associated with the behavior of the disease [50, 80-86] 
(Table 2). Thus, both tumors carrying monosomy 22 and 
those displaying diploid karyotypes, have been associated 
with a better outcome [87] than that of cases with more 
complex karyotypes who show shorter recurrence-
free survival rates [41, 88, 89]. Most interestingly, 
simultaneous presence of monosomy 14 and del (1p) in 
the ancestral tumor cell clones has been shown to be an 
adverse independent prognostic marker for disease-free 
survival in meningiomas [41]. 
In parallel, single nucleotide polymorphism (SNP)-
array studies have confirmed and extended the available 
information about the distinct cytogenetic subgroups of 
meningiomas [4, 21, 34]. Thus, Lee et al. [21] described 
5 ‘classes’ of meningiomas based on gene expression 
analyses that showed a high correlation with their copy 
number alteration profile by SNP-arrays, as well as the 
tumor recurrence status and histopathology. Similarly, 
Tabernero et al. [4] confirmed by SNP-arrays that 
meningiomas can be classified into 3 major cytogenetic 
subgroups: diploid cases, meningiomas with a single 
chromosomal change [e.g. monosomy 22/22q-] and tumors 
with complex karyotypes including cases with ≥2 altered 
chromosomes. Of note, such cytogenetic classification 
of meningiomas was recently shown to be the most 
powerful independent predictor of outcome (e.g. 10–year 
recurrence-free survival rates of 91±6%, 90±4%, 67±8%, 
respectively) particularly when evaluated in combination 
with patient age and tumor size, localization and WHO 
grade [90].
Regarding GEP, Watson et al. [91], in a pioneering 
study in meningiomas, reported GEP of tumor cells to be 
associated with the WHO grade. Such association has been 
subsequently confirmed by others [59, 91, 92], and Fevre-
Montange et al [92] and Serna et al [84] also reported 
an association of GEP with the main histopathological 
subtypes of grade I meningiomas. Similarly, unique GEP 
of meningioma cells have also been associated with tumor 
localization (e.g. spinal vs. intracranial tumors) [93], 
patient gender [94] and clinically relevant cytogenetic 
subgroups of meningiomas (i.e. diploid tumors vs cases 
with isolated monosomy 22/del(22q) vs meningiomas with 
complex karyotypes) [50].
Most interestingly, GEP of meningiomas have 
shown the existence of heterogeneous profiles which 
are associated with a different tumor behavior, even 
within the same WHO grade; thus, GEP of tumor 
cells from aggressive and/or invasive meningiomas 
emerged as being unique [44, 74, 84, 92] and typically 
associated with both high-proliferative gene expression 
signatures [95] and a high-risk of recurrence [50, 74, 
84]. In this regard, Carvalho et al. [95] showed that 
meningiomas fall into two main molecular subgroups 
designated as ‘low-proliferative’ and ‘high-proliferative’ 
meningiomas, according to their different GEP and 
median MIB-1 labeling indices. Similarly, Perez-Magan 
et al. [74] identified a 49-gene signature of meningioma 
aggressiveness that characterizes histologically benign 
meningiomas which may recur. 
concludInG reMArKs
Important advances have been achieved in the last 
decades in our understanding of the genetic/chromosomal 
alterations of meningiomas. Thus, current knowledge 
point out to the existence of several different pathways 
of tumorigenesis and clonal evolution which may target 
different genes in low vs high-grade tumors, as well as 
among low grade meningiomas. Thus, although NF2 
mutation in association with monosomy 22 is the most 
frequently observed alteration of a single gene, early 
mutations involving genes other than NF2 (e.g. AKT1, 
SMO, TRAF7, KLF4) have recently emerged as alternative 
oncogenic pathways in NF2 non-mutated tumors. In 
addition, other genetic and/or chromosomal alterations 
are present in around one third of cases typically in the 
context of more complex karyotypes; such complex 
karyotypes appear to develop through multiple different 
pathways of clonal evolution which typically implicate 
several intracellular signaling pathways associated with 
cell proliferation, migration and apoptosis. Independently 
of the precise pathways of clonal evolution involved, 
accumulation of cytogenetic alterations, as reflected by 
more complex karyotypes with ≥2 altered chromosomes, 
usually leads to more aggressive disease, higher tumor 
grade and a poorer outcome in terms of recurrence-
free survival. Consequently, assessment of tumor 
cytogenetics at diagnosis together with other clinical and 
histophatological features of the disease, becomes critical 
for both the establishment of optimal follow-up strategies 
and the definition of the most appropriate treatment for 
individual patients.
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